Market Alert: Ukraine Conflict Update and U.S. Policy Risk

dorsaVi Strengthens Leadership for Next Growth Phase

Aug 28, 2025

dorsaVi Ltd (ASX: DVL), a pioneer in wearable motion analysis and sensor technologies, has appointed Mathew Regan as Group Chief Executive Officer, effective 1 November 2025. Regan, formerly CEO of Artrya Limited, brings extensive experience in digital health, AI, advanced manufacturing, and global technology scaling. His appointment comes as dorsaVi advances commercialization of its RRAM-enabled sensor architecture and Reflex platform, targeting high-growth markets including robotics, neuromorphic computing, and edge AI. Complementing this, the company recently launched Artemis Labs to accelerate development of next-generation human–machine interface technologies.

While Regan drives strategic expansion and partnerships, Andrew Ronchi will continue as CEO of dorsaVi’s sensor division, focusing on scaling U.S. sales and enhancing adoption of its FDA-cleared movement analytics platform. With a strong base in workplace safety and clinical applications, dorsaVi is positioned to expand its innovative technology into broader global markets.

 

 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com